Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
49.31
-0.25 (-0.50%)
At close: Jun 16, 2026, 4:00 PM EDT
49.16
-0.15 (-0.30%)
Pre-market: Jun 17, 2026, 8:14 AM EDT
Vaxcyte Employees
Vaxcyte had 507 employees as of December 31, 2025. The number of employees increased by 93 or 22.46% compared to the previous year.
Employees
507
Change (1Y)
93
Growth (1Y)
22.46%
Revenue / Employee
n/a
Profits / Employee
-$1,866,927
Market Cap
7.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 507 | 93 | 22.46% |
| Dec 31, 2024 | 414 | 160 | 62.99% |
| Dec 31, 2023 | 254 | 96 | 60.76% |
| Dec 31, 2022 | 158 | 69 | 77.53% |
| Dec 31, 2021 | 89 | 31 | 53.45% |
| Dec 31, 2020 | 58 | 15 | 34.88% |
| Dec 31, 2019 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Apogee Therapeutics | 261 |
| Kymera Therapeutics | 253 |
| Praxis Precision Medicines | 168 |
PCVX News
- 1 day ago - Vaxcyte Transcript: AGM 2026 - Transcripts
- 13 days ago - Vaxcyte Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 14 days ago - Vaxcyte doses first participant in VAX-A1 study - TheFly
- 14 days ago - Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - GlobeNewsWire
- 15 days ago - Vaxcyte Slides: Corporate presentation - Filings
- 5 weeks ago - Vaxcyte Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Vaxcyte reports Q1 EPS ($2.30), consensus ($1.77) - TheFly
- 5 weeks ago - Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire